VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive shift in its earnings outlook. This upgrade is driven by a consistent upward trend in earnings estimates, a key factor influencing stock prices. The Zacks Rank system, known for its focus on earnings estimate revisions, assigns a rating based on the company’s changing earnings picture. As a result, VistaGen Therapeutics stands out as a strong candidate for potential market-beating returns in the near term.